Beximco Pharmaceuticals Limited

BXPHealthcare
36.73GBX
2.04%
Market Cap
163.87M
Volume
3k
9% of avg
P/E Ratio
0.05
EPS (TTM)
8.14
Beta
0.63
Day Range
36.73p - 36.73p
52 Week Range
19.33p36.73p41.00p
36.73p

Upcoming Events

20 May 2025
High Court hearing on BSEC order
High Impact Event
June 30, 2025
Expected date for full year results 2024-25
High Impact Event
July 2025
Expected full-year results announcement
High Impact Event
Early Q3 2025
Potential trading update for Q3 2024-25
High Impact Event
29 July 2025
Expected Full Year Results 2024-25 (estimated)
High Impact Event
BXP
NEUTRAL

Beximco Pharma Requests Extension to Publish Q3 Results

The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.

BXP
NEUTRAL

Beximco Pharma Denies Corruption Allegations, Provides Update on Regulatory Order

The pharmaceutical company denies allegations of corruption in Covid-19 vaccine procurement and provides an update on a regulatory order regarding its board of directors.

BXP
NEUTRAL

Beximco Pharma Faces Regulatory Uncertainty Over Board Appointments

The pharmaceutical company faces regulatory uncertainty over the proposed appointment of additional independent directors to its board, with a court decision expected by mid-March.

BXP
NEUTRAL

Beximco Pharma Announces Board Change

The pharmaceutical company has announced a change in its Board of Directors, with a new Non-Executive Director nominated by a major shareholder.

BXP
GOOD

Beximco Pharmaceuticals Reports Strong Half-Year Results with 17.5% Profit Growth

The generic drug manufacturer reported an 8.8% increase in net sales and a 17.5% rise in profit after tax for the half-year. Export sales surged by 31.6%, with expansion into new markets.

BXP
NEUTRAL

Beximco Pharma Faces Board Shake-Up as Regulator Seeks to Appoint New Directors

Pharmaceutical company faces potential Board shake-up as regulator seeks to appoint new directors

BXP
NEUTRAL

Beximco Pharmaceuticals Holds Annual General Meeting

The pharmaceutical company held its Annual General Meeting, approving a 40% cash dividend and a name change, but the announcement contains no major updates.

BXP
NEUTRAL

Beximco Pharma Announces AGM, Dividend and Name Change

Pharmaceutical company Beximco announces upcoming AGM and routine corporate updates.

BXP
NEUTRAL

Beximco Pharma Reports Modest Q1 Revenue Growth, Confident in Execution

Pharmaceutical company reports modest Q1 revenue growth, but remains confident in its business strategy.

BXP
GOOD

Beximco Pharma Wins Supreme Court Appeal, Trading Suspension Lifted

The pharmaceutical manufacturer has won its appeal against an interim court order, leading to the lifting of a temporary trading suspension on its shares.